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Background: Cancer treatment and outcomes can be influenced by tumor characteristics,
patient overall health status, and comorbidities. While previous studies have analyzed the
influence of comorbidity on cancer outcomes, limited information is available regarding
factors associated with the increased prevalence of comorbidities and multimorbidity among
patients with colorectal cancer in Spain.
Patients and Methods: This cross-sectional study obtained data from all colorectal cancer
cases diagnosed in two Spanish provinces in 2011 from two population-based cancer registries
and electronic health records. We calculated the prevalence of comorbidities according to patient
and tumor factors, identified factors associated with an increased prevalence of comorbidity and
multimorbidity, analyzed the association between comorbidities and time-to-surgery, and devel-
oped an interactive web application (https://comcor.netlify.com/).
Results: The most common comorbidities were diabetes (23.6%), chronic obstructive
pulmonary disease (17.2%), and congestive heart failure (14.5%). Among all comorbidities,
52% of patients were diagnosed at more advanced stages (stage III/IV). Patients with
advanced age, restricted performance status or who were disabled, obese, and smokers had
a higher prevalence of multimorbidity. Patients with multimorbidity had a longer time-to-
surgery than those without comorbidity (17 days, 95% confidence interval: 3–29 days).
Conclusion: We identified a consistent pattern of factors associated with a higher preva-
lence of comorbidities and multimorbidity at diagnosis and an increased time-to-surgery
among patients with colorectal cancer with multimorbidity in Spain. This pattern may
provide insights for further etiological and preventive research and help to identify patients
at a higher risk for poorer cancer outcomes and suboptimal treatment.
Keywords: colorectal cancer epidemiology, comorbidity, multimorbidity, elderly
Introduction
Globally, cancer accounted for 9.6 million deaths in 2018 and was the second most
common cause of death.1 Colorectal cancer (CRC) is the most frequently diagnosed
cancer in Spain.2,3 Older CRC patients are underrepresented in clinical trials largely
related to their high prevalence of comorbidity.4
Comorbidity describes a long-term health condition or disorder occurring alongside
the primary disease of interest, such as cancer,5 whereas multimorbidity refers to the
existence of two or more comorbid conditions.6 Comorbidity and multimorbidity are
increasingly seen as a problem of the elderly but have also been increasingly reported at
a younger age in patients with lower socioeconomic status.7,8
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Despite the common coexistence of comorbidity and
cancer, the guidelines and delivery of cancer care generally
focus on single disease management.9,10 However, effective
management of comorbid conditions is important in optimiz-
ing patients’ health status11 and decisions regarding cancer
treatment require careful consideration of comorbidities.12–14
Furthermore, postoperative complications occur more fre-
quently in patients with comorbidity15 and certain comorbid
conditions have been linked to adverse outcomes following
surgery for cancer.12,16
While evidence of the influence of comorbidities on
cancer outcomes is consistent, little is known about factors
associated with a higher prevalence of comorbidities
among CRC patients and their association with the time
from cancer diagnosis to surgery. Thus, the present study
determined the prevalence of individual comorbidities,
characterized patient and tumor factors associated with
a higher prevalence of individual comorbidities and multi-
morbidity at diagnosis, and analyzed the association
between comorbidities and time-to-surgery among CRC
patients at diagnosis in two Spanish provinces (Granada
and Girona) in 2011. Furthermore, we studied the extent to
which the prevalence of comorbidities among CRC
patients was similar to the prevalence in the general
Spanish population in 2011.
Materials and Methods
Study Design, Participants, Data, and
Setting
This population-based cross-sectional study included all the
primary CRC incident cases diagnosed in 2011 in two
Spanish population-based cancer registries (Girona and
Granada), registered with codes C18-C21 according to the
International Classification of Diseases for Oncology, third
edition (ICD-O-3).17
Comorbidity information and clinical data were obtained
retrospectively from a review of patient electronic health
records (EHRs) including primary care, pathology, out-
patient, and in-patient hospital information. The data collection
followed a detailed protocol from the European High-
Resolution studies collaboration (TRANSCAN-HIGHCARE
project within ERA-Net).18 Aggregated data to study the pre-
valence of comorbidities among the general Spanish popula-
tion by age groups in 2011 were obtained from the Spanish
Primary Care Clinical database from the Spanish Ministry of
Health, Consumer Affairs and Social Welfare available at
https://pestadistico.inteligenciadegestion.mscbs.es/.
The study proposal (CP17/00206) was approved by the
internal review board of the Andalusian School of Public
Health and the ethics committee from the Department of
Health of the Andalusian Regional Government (study
0072-N-18). The study was carried out in accordance
with the principles of the Declaration of Helsinki. No
samples were used, all data accessed for the study were
fully anonymized and the informed consent was waived.
The data are held by the Regional Government of
Andalusia and the Andalusian Health Department.
Variables
We recorded patient age, sex, smoking status, body mass
index (BMI), performance status, comorbidities, and multi-
morbidity. Age at diagnosis was categorized into four groups:
<55, 55–64, 65–74, and ≥75 years. Smoking status was
categorized as current, previous, and never smoker. BMI
was categorized as underweight-normal (<25.0 kg/m2), over-
weight (≥25.0 kg/m2 and <30 kg/m2), and obese (≥30 kg/m2).
We combined the underweight and normal-weight categories
because of data sparsity (fewer than five patients were under-
weight). The patients’ performance status was ascertained
based on their medical records using the Eastern Cooperative
Oncology Group (ECOG) scale (Supplementary Table S1).20
Comorbidities were assessed from patient EHRs using
the International Classification of Diseases (ICD)-10 codes
(Supplementary Table S2). All comorbidities recorded in
the EHRs were included except for those diagnosed within
6 months before cancer diagnosis to prevent the inclusion
of CRC-related comorbidities.21 The CRC patients’
comorbidities were classified based on the Royal College
of Surgeons-modified Charlson score, which reduces the
number of comorbidities to 12, removes a category (peptic
ulcer disease), and groups diseases (e.g., diabetes mellitus
codes with or without complications are grouped into
a single category). The score does not assign weights to
individual comorbidities.22 The final score simply counts
the total number of comorbidities for each patient as no
comorbidities (0), one comorbidity (1), and two or more
(≥2) comorbidities, with (≥2) comorbidities defined as
multimorbidity.22
We recorded the tumor topography, morphology, and
grade of differentiation, which were coded according to
ICD-O-3. The final-stage variable was defined as the com-
bination of clinical and pathological TNM stages and
categorized into four groups, based on the seventh edition
of the TNM manual (AJCC staging system).23
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The time from cancer diagnosis to surgery (time-to-
surgery) was calculated as the number of days elapsed
from the date of cancer diagnosis to the date of surgical
intervention.
Statistical Analysis
First, we calculated the prevalence of each comorbidity.
However, we only present here the results for 10 comor-
bidities, as HIV and hemiplegia/paraplegia were only
represented by four and three cases, respectively. Then,
we calculated the counts and proportions of these comor-
bidities by patient and tumor factors using chi-square and
Fisher’s exact tests for statistical inference and the score
test of trend for the assessment of linear trends.
To characterize the patient and tumor factors associated
with a higher prevalence of multimorbidity (≥2 chronic
conditions vs none) and comorbidity (one chronic condition
vs none) at diagnosis, we used a multinomial regression to
derive crude and adjusted (for sex and age) prevalence
ratios (PRs) with their respective 95% confidence intervals
(CIs) using the category of non-comorbidities as the refer-
ence. The PRs indicated the magnitude of the prevalence of
comorbidity and multimorbidity among a group of CRC
patients with a particular patient or tumor factor relative to
another group without the given factor at the moment of
cancer diagnosis.24 Furthermore, we compared the preva-
lence of the most common comorbidities among CRC
patients with the prevalence of comorbidities among the
Spanish general population by age groups.
We used medians and interquartile ranges (IQRs) to
describe the time-to-surgery according to patient age, stage,
and comorbidity status. Finally, we used a nonparametric
robust regression to analyze the association of comorbidities
and multimorbidity with time-to-surgery. Nonparametric
regression models the mean of the outcome conditional on
the covariates but, unlike linear regression, it makes no
assumptions about the functional form of the relationship
between the outcome and the covariates.25,26 We used time-
to-surgery in days as the dependent variable and the Royal
College of Surgeons-modified Charlson score as the inde-
pendent variable adjusted for age and cancer stage. We used
cross-validation to choose the best data bandwidth for the
local linear regression to estimate the time-to-surgery condi-
tional mean as a function of the changes in age and cancer
stage.25,26 We used 1000 bootstrapped samples to compute
the 95% CIs. Then, we derived the model’s predicted mar-
ginal time-to-surgery mean and plotted it as a function of age
and cancer stage.
We assumed that missing information was completely at
random and performed a complete case analysis. We used
Stata v.15.1 (StataCorp, College Station, Texas, US) and the
commands “npregress”, “margins”, and “marginsplot” for
statistical analysis and developed an interactive web applica-
tion presenting the results of the study (https://watzilei.com/
shiny/CoMCoR/).
Results
Patient and Tumor Characteristics
Diabetes mellitus, chronic obstructive pulmonary disease
(COPD), and congestive heart failure were the most common
comorbidities among the 1061 CRC cases included in the
study (24%, 17%, and 15%, respectively) (Supplementary
Table S3).
Supplementary table S4 shows the sociodemographic and
tumor characteristic from the 1061 CRC cases. Sixty-one
percent of the CRC cases were men and 67% were aged
>65 years. Furthermore, 40.4% of CRC cases were previous
or current smokers, 49.0% were overweight or obese, and
11.8% had a restricted performance status (i.e., unable to
work and limited self-care). The tumor anatomical sites
included the right colon (33.6%), left colon (32.1%), rectum
(33.3%), and unspecified (1.0%). The grades of tumor differ-
entiation were mostly grade two (56.2%); however, 18.9% of
the tumors were not graded. Only 15.8% of CRC patients had
a stage I tumor at diagnosis and 52.1% of cases were identi-
fied as stage III/IV. More than half (58.9%) of CRC patients
had one or more comorbidities and 30.5% had multimorbid-
ity. Among patients with multimorbidity, the maximum num-
ber of comorbidities was six (in four patients)
(Supplementary Table S4). The prevalence of the most com-
mon comorbidities among CRC patients was remarkably
higher than in the Spanish general population for all the
categories of age in 2011. For instance, the prevalence of
diabetes among CRC patients >74 years was approximately 3
times than in the group of the same age in the overall Spanish
population, i.e., 26.4% vs 8.9% (Supplementary Table S5).
Patient Factors
Table 1 shows the distribution and frequency of patient
and tumor factors for the top five comorbidities plus
dementia. Overall, there was a gradient in the prevalence
of comorbidities by age (score test for trend, chi-square:
129.1, p-value: 0.0001). Compared to those <55 years of
age, CRC patients aged ≥75 years showed a nearly eight-
fold higher prevalence of congestive heart failure and
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a nearly six-fold higher prevalence of type-II diabetes
mellitus and dementia. The prevalence of comorbidities
was higher among men than among women. Diabetes and
COPD were the most common comorbidities among men.
However, women showed a higher prevalence of dementia
and rheumatologic disease (6.6% vs 3.3% and 15.1% vs
6.7%). Among the top five comorbidities plus dementia,
congestive heart failure had the highest prevalence among
patients with restricted performance status (34.3%) and
disability (66.7%), whereas COPD had the highest preva-
lence among current and previous smokers. There was
strong evidence supporting a significant trend in the pre-
valence of comorbidities across the levels of performance
status for the five most common comorbidities plus
dementia (score test for trend, chi-square: 71.5, p-value:
0.0001) (Table 1).
Furthermore, CRC patients with COPD and diabetes
showed the highest prevalence of current smokers (27.0%
and 23.8%, respectively). Current smokers among CRC
patients with COPD were 2.5 more prevalent than never-
smokers. CRC patients with diabetes showed the highest
prevalence of overweight and obesity (22.7% and 31.1%,
respectively) while CRC patients with dementia had the
lowest prevalence (Table 1).
Tumor Factors
Overall, the tumor factors showed a weak association with
a higher prevalence of comorbidity at diagnosis. The most
common anatomical sites for the top five comorbidities
plus dementia were the right and left sides of the colon.
Compared to the other comorbidities, dementia showed the
highest ratio of grade IV vs grade I of differentiation
(Table 1).
Comorbidity and Multimorbidity by
Patient and Tumor Factors
Table 2 shows the PRs of multimorbidity and comorbidity
vs the absence of comorbidities at diagnosis by patient and
tumor factors. Overall, male CRC patients who were older,
obese, current smokers, and with restricted performance
status or disability had a higher prevalence of multimor-
bidity. For instance, the prevalence of multimorbidity was
2.7 times higher in current smokers (95% CI: 1.6–4.8) than
that in non-smokers while the prevalence of multimorbid-
ity in obese CRC patients was 2.4 times (95% CI: 1.4, 4.0)
that in CRC patients with a BMI <25 km/m2 at diagnosis
(Table 2).
Time-to-Surgery
Figure 1A shows a right-skewed distribution of the time
from CRC diagnosis to surgery. The minimum time-to-
surgery was 0 days in 171 patients (11%), representing
a CRC diagnosis during surgery. The maximum time was
587 days in one patient. Among patients with diagnosis at
surgery, 46% did not have comorbidities, 34% had one
comorbidity, and 20% had multimorbidity. The 5th, 25th,
50th, 75th, and 95th percentiles of time-to-surgery were 0,
5, 35 (median), 80, and 177 days, respectively. The
observed mean and standard deviation for the time-to-
surgery were 55 (95% CI: 52–61 days) and 66 days,
respectively. The median and IQR for time-to-surgery by
comorbidity status were: 30 days (IQR: 89) for no comor-
bidities, 31 days (IQR: 65) for one comorbidity, and 46
days (IQR: 69) for multimorbidity (Figure 1B).
Table 3 shows the estimated difference in time-to-
surgery for one comorbidity and multimorbidity compared
to that in the group with no comorbidity, adjusted for
patient age and disease stage. The time-to-surgery for
patients with one comorbidity was 5.2 days (95% CI:
−1.3–11.6) longer than that for patients without comorbid-
ity; however, this difference was not statistically signifi-
cant. In contrast, we detected a significantly longer time-to
-surgery in patients with multimorbidity than that in
patients without comorbidity (16.7 days longer; 95% CI:
3.2–29.4). Figure 2 shows the predicted marginal mean of
time-to-surgery by patient comorbidity status adjusted for
age and stage. Overall, multimorbidity increased the time
from cancer diagnosis to surgery across all ages and stages
(Figure 2).
Discussion
We identified a particular pattern of patient and tumor
factors associated with a higher prevalence of comorbid-
ities and multimorbidity at diagnosis among CRC patients
in two Spanish provinces and an increased time-to-surgery
in patients with multimorbidity compared to that in those
without comorbidities. The prevalence of multimorbidity
at diagnosis was higher in male CRC patients with
advanced age, restricted performance or disability, obesity,
and smoking habits.
There is a scarcity of literature reporting the prevalence
of diabetes among CRC patients.27 However, we found
that diabetes was the most prevalent comorbidity among
CRC patients (24%). Among non-cancer populations, the
prevalence of diabetes in adults in Spain ranges between
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6% and 11%.28 Our findings were similar to those pre-
viously reported in a Taiwanese cohort of 1197 CRC
patients, in which 24% had a reported history of
diabetes.29 Diabetes has also been associated with
a higher incidence of CRC and a shorter CRC survival.30
Therefore, public health programs targeting CRC preven-
tion strategies among diabetic patients might have
a positive impact on CRC outcomes in Spain.
Table 1 Distribution and Frequency of Patient and Tumor Factors for the Top Five Comorbidities Plus Dementia by Patient and











n % n % n % n % n % n %
Patient’s Factors
Age in Years
<55 130 4 3.1 9 6.9 2 1.5 8 6.2 6 4.6 6 4.6
55–64 219 17 7.8 22 10.1 5 2.3 21 9.7 13 6.0 42 19.4
65–74 272 34 12.6 36 13.4 5 1.9 57 21.0 30 11.2 86 32.0
≥75 440 99 23.3 57 13.4 36 8.5 96 23.0 55 12.9 116 27.3
Sex
Male 644 96 15.2 76 12.0 21 3.3 143 23.0 42 6.7 171 27.1
Female 417 58 14.1 48 11.7 27 6.6 39 9.5 62 15.1 79 19.3
Performance Status
Normal (0) 259 20 7.8 12 4.7 1 0.4 25 9.7 19 7.4 45 17.5
Restricted but able to carry out light work (1) 423 68 16.1 62 14.7 13 3.1 89 21.0 66 15.6 117 27.7
Restricted, unable to work but capable of self-care (2) 83 21 25.6 10 12.2 8 9.8 16 20.0 9 11.0 25 30.5
Restricted, capable of limited self-care (3) 35 12 34.3 9 25.7 6 17.1 8 23.0 4 11.4 14 40.0
Disabled (4) 6 4 66.7 2 33.3 2 33.3 2 33.0 2 33.3 1 16.7
Smoking Status
Current 130 12 9.2 15 11.5 5 3.8 35 27.0 9 6.9 31 23.8
Previous 298 55 18.5 35 11.7 9 3.0 80 27.0 16 5.4 87 29.2
Never 505 68 13.5 65 12.9 25 5.0 54 11.0 67 13.3 104 20.6
BMI in kg/m2
<25 226 17 7.5 23 10.2 12 5.3 40 18.0 22 9.7 40 17.7
25.0–29.9 327 40 12.2 42 12.8 10 3.1 41 13.0 25 7.6 74 22.7
≥30 193 30 15.5 33 17.1 7 3.6 49 25.0 21 10.9 60 31.1
Tumor Factors
Anatomical Site
Right Colon 357 55 15.7 44 12.5 21 6.0 67 19.1 31 8.8 98 28.8
Left Colon 340 50 14.9 41 12.2 11 3.3 63 18.8 33 9.9 74 22.1
Rectal 353 47 13.5 38 10.9 16 4.6 51 14.7 39 11.2 76 21.8
Colon Unspecified 11 2 28.6 1 14.3 0 - 1 14.3 1 14.3 2 28.6
Grade
I 168 24 15.2 19 12.0 3 1.9 21 13.3 19 12.0 36 22.8
II 596 83 14.0 77 13.0 27 4.6 116 19.5 56 9.4 138 23.3
III 90 13 14.6 7 7.9 2 2.2 12 13.5 8 9.0 30 33.7
IV 7 1 14.3 0 - 1 14.3 0 - 1 14.3 0 -
Stage
I 168 25 15.0 18 10.8 6 3.6 23 13.8 17 10.2 34 20.4
II 281 51 18.4 31 11.2 13 4.7 57 20.6 42 15.2 69 25.0
III 285 29 10.4 39 13.9 11 3.9 54 19.3 16 5.7 79 28.2
IV 267 43 16.2 34 12.8 13 4.9 37 14.0 28 10.6 54 20.4
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We also observed a high prevalence of stage III/IV. The
prevalence was even higher in older CRC patients affected
by dementia. These findings may be related to the low
utilization of CRC screening in Spain. In 2011, CRC
screening programs were implemented in only nine
Spanish regions, with partial coverage.32 A recent study
in Denmark reported a lower prevalence of advanced
cancer stage at diagnosis among CRC patients who were
offered screening.31 However, further research is war-
ranted to explore the status of the implementation of
CRC screening in Spain and its public health impact in
terms of early diagnosis and cancer stage. While all
Table 2 Patient and Tumor Factors Associated with Higher Prevalence of Comorbidity (One) and Multimorbidity (Two or More
Comorbidities) Among Colorectal Cancer Patients at Diagnosis in Granada and Girona, 2011, n = 1061











<55 130 25 (19.3) (Reference) (Reference) 11 (8.5) (Reference) (Reference)
55–64 216 63 (29.2) 2.0 (1.2, 3.4) 2.0 (1.2, 3.4) 35 (16.2) 2.5 (1.2, 5.3) 2.4 (1.2, 5.1)
65–74 269 82 (30.5) 3.3 (1.9, 5.6) 3.2 (1.9, 5.5) 93 (34.6) 8.5 (4.3, 16.8) 8.2 (4.1, 16.3)
≥75 423 131 (31.0) 4.6 (2.8, 7.6) 4.6 (2.7, 7.7) 185 (43.7) 14.8 (7.6, 28.8) 14.9 (7.6, 29.2)
Sex
Male 630 183 (29.0) (Reference) (Reference) 215 (34.1) (Reference) (Reference)
Female 408 118 (28.9) 0.8 (0.6, 1.1) 0.8 (0.6, 1.1) 109 (26.7) 0.6 (0.5, 0.9) 0.6 (0.4, 0.8)
Performance Status (ECOG)
Normal (0) 257 59 (23.0) (Reference) (Reference) 40 (15.6) (Reference) (Reference)
Restricted but able to carry out light work (1) 422 137 (32.5) 2.8 (1.9, 4.1) 2.5 (1.7, 3.7) 154 (36.5) 4.6 (3.1, 7.1) 2.0 (0.9, 4.6)
Restricted, unable to work but capable of self-care (2) 82 25 (30.5) 3.2 (1.7, 6.1) 2.3 (1.1, 4.6) 36 (43.9) 6.8 (3.6, 12.8) 7.0 (3.3, 14.9)
Restricted, capable of limited self-care or disabled (3, 4) 40 11 (27.5) 7.4 (2.3, 24.0) 5.9 (1.7, 19.6) 25 (62.5) 24.7 (8.1, 75.0) 9.4 (4.5, 19.7)
Smoking Status
Current 130 42 (32.3) 1.3 (0.8, 2.1) 2.1 (1.3, 3.6) 40 (30.1) 1.3 (0.8, 2.1) 2.7 (1.6, 4.8)
Previous 297 89 (30.0) 1.4 (1.0, 2.0) 1.6 (1.0, 2.5) 113 (38.0) 1.9 (1.3, 2.7) 2.2 (1.4, 3.4)
Never 503 145 (28.8) (Reference) (Reference) 137 (27.2) (Reference) (Reference)
BMI in kg/m2
<25 226 72(31.9) (Reference) (Reference) 57(25.2) (Reference) (Reference)
25.0–29.9 326 87(26.7) 0.8 (0.5, 1.2) 0.8 (0.5, 1.2) 89(27.3) 1.0 (0.7, 1.5) 1.0 (0.6, 1.6)
≥30 193 52(26.9) 1.1 (0.7, 1.8) 1.2 (0.7, 1.9) 79(40.9) 2.2 (1.4, 3.5) 2.4 (1.4, 4.0)
Tumor Factors
Anatomical Site
Right Colon 357 102(29.3) (Reference) (Reference) 118(33.9) (Reference) (Reference)
Left colon 340 93(27.8) 1.1 (0.7, 1.5) 0.9 (0.6, 1.3) 104(31.0) 1.3 (0.9, 1.9) 0.8 (0.6, 1.2)
Rectal 353 106(30.5) 0.9 (0.6, 1.3) 1.0 (0.7, 1.4) 99(28.5) 1.1 (0.8, 1.6) 0.8 (0.5, 1.1)
Grade
I 158 48(30.4) (Reference) (Reference) 44(27.8) (Reference) (Reference)
II 592 169(28.6) 1.0 (0.6, 1.5) 0.9 (0.6, 1.3) 189(31.9) 1.2 (0.8, 1.9) 1.0 (0.6, 1.6)
III-IV 96 27(28.1) 0.9 (0.5, 1.6) 0.8 (0.4, 1.4) 27(28.1) 1.0 (0.5, 1.8) 0.8 (0.4, 1.6)
Stage
I 167 46(27.5) (Reference) (Reference) 47(28.1) (Reference) (Reference)
II 276 85(30.1) 1.5 (0.9, 2.4) 1.3 (0.8, 2.1) 99(35.9) 1.7 (1.0, 2.7) 1.3 (0.8, 2.1)
III 279 76(27.2) 1.1 (0.7, 1.7) 1.0 (0.6, 1.7) 89(31.9) 1.2 (0.8, 1.9) 1.1 (0.7, 1.8)
IV 265 85(32.1) 1.3 (0.8, 2.0) 1.2 (0.7, 1.9) 72(27.2) 1.0 (0.7, 1.7) 0.9 (0.5, 1.5)
Notes: Age was adjusted for sex and sex was adjusted for age. Complete case analysis: there were 20 (1.9%) missing values for comorbidities; 256 (24.1%) for performance
status; 128 (12.0%) for smoking status; 315 (26.7%) for BMI, and 60 (5.7%) for stage.
Abbreviations: CPR, crude prevalence ratio; APR, adjusted for age and sex prevalence ratio.
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populations would benefit from the systematic use of
screening, socioeconomically disadvantaged groups, such
as patients with dementia, may especially benefit from
targeted CRC screening.33
We observed an increasing trend of comorbidities by
age. Overall, over 60% of all cases of cancer are diagnosed
after age 65 years of age, with 67% of cancer deaths
occurring in this age group.34 Many reasons might explain
why cancer occurs more frequently in older persons. The
elderly have less resistance and longer exposure to carci-
nogens, a decline in immunity, altered anti-tumor defenses,
decreased DNA repair, defects in tumor-suppressor genes,
and differences in biological behavior including angiogen-
esis. These factors, together with comorbidities, might
adversely affect cancer diagnosis, treatment options, and
survival in the elderly population.35
Given the increased prevalence of multimorbidity in
older age groups, health-care professionals need to be
vigilant for common comorbidities when offering care
for these patients because of the tendency toward poor
treatment tolerance and occurrence of complications
related to the interaction between age-related physiological
changes and comorbidity.35 Improved coordination
between surgical and medical disciplines is required to
optimize the pre-existing comorbid condition for the best
cancer survival outcomes and minimal occurrence of treat-
ment complications.
Although cancer stage at the time of CRC diagnosis is
a crucial determinant of outcome, comorbidity increases
the complexity of cancer management and affects survival.
Research on cancer control and treatment should address
multimorbidity, particularly in the elderly.36 Research is
needed to assess the role of comorbidity in the benefit-
harm ratio of treatment options in elderly patients to
improve clinical guidelines to support individualized deci-
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Figure 1 Distribution of the time from colorectal cancer diagnosis to surgery by comorbidities status among all incident colorectal cancer patients in Granada and Girona,
2011, n = 1061 ((A): Histogram and kernel density and (B): Box plot).
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There is no conclusive evidence supporting an optimal
window of time from cancer diagnosis to surgical treat-
ment. However, a study from the American College of
Surgeons reported that patients who underwent cancer
operation at precisely 8 weeks (56 days) after the end of
neoadjuvant chemoradiotherapy had the best overall
survival and successful removal of their residual
tumors.37 Another study found that CRC patients waiting
for longer than 12 weeks (84 days) to receive surgery had
an increased all-cause mortality compared to those who
received surgery within 4 weeks (28 days).38 A study of
patients receiving elective surgery for colonic resection
following CRC diagnosis in Ontario found that older age
and comorbidity were among the factors that influenced
the receipt of treatment after 42 days from diagnosis.39
The cross-sectional nature of our study design is
a limitation and it does not allow for public health recom-
mendations (i.e., targeted CRC screening) or a causal
interpretation of the associations given the absence of
a temporal link. Another limitation is the absence of infor-
mation on certain lifestyle characteristics (exercise, diet,
and drinking habits) that may also affect the prevalence of
lifestyle-related comorbidities. We assumed that data were
missing at random and performed a complete case analy-
sis. Only 2% of data on the main outcome (comorbidities)
were missing. Furthermore, the study is based on data
from two Spanish provinces, which limits the generaliz-
ability of the findings. However, our results are consistent
with current evidence regarding the prevalence of comor-
bidities and, to the best of our knowledge, is the first to
identify the most prevalent comorbidities among CRC
Table 3 Nonparametric Regression Estimates from Time-to-
Surgery by Patients’ Comorbidity Status, Age and Cancer Stage






One 5.24 (−1.31, 11.65)
Two or more 16.74 (3.23, 29.42)
Age in years
For one-unit increase −1.11 (−1.6, −0.80)
Cancer Stage
I Reference
II −5.31 (−10.68, 0.58)
III 0.51 (−8.43, 10.42)
IV 1.22 (−12.30, 17.35)
Notes: Bold figures highlight statistically significant values (i.e., it does not include
the zero). *Bootstrapped 95% confidence intervals.
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Figure 2 Mean nonparametric estimated time-to-surgery by patients’ comorbidity status, age and cancer stage, in Granada and Girona, 2011, n = 1061.
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patients at diagnosis and to provide evidence of an
increased time-to-surgery for CRC patients with multimor-
bidity in Spain. Furthermore, while clinical studies are
representative of only a selected part of the population,
ours is a population-based observational study using can-
cer registry and EHRs data.
Different approaches to measuring comorbidity specifi-
cally in cancer patients include focusing on single comorbid
conditions in isolation or weighted indices such as the
Charlson comorbidity index,40 Adult Comorbidity
Evaluation – 27 index (ACE-27),41 and Elixhauser index.42
However, to date, there is no agreed gold standard method
upon which to measure comorbidity in the cancer patient
population.43 We used the Royal College of Surgeons sys-
tem, which is a clinical score used to evaluate the risk of
death during surgery. The score applies equal weights to 12
comorbidities categorized as 0, 1, or 2 or more comorbidities,
making it easy to use, since all comorbidities are considered
equally important.22
In summary, we identified a pattern in the distribution
and frequency of patient and tumor factors associated with
the higher prevalence of comorbidities and multimorbidity
at diagnosis among CRC patients in Spain. Particularly,
male CRC patients with advanced age, restricted perfor-
mance or disability, obesity, and smoking habits had higher
prevalence of multimorbidity at diagnosis. Furthermore,
CRC patients with multimorbidity showed an increased
waiting time from cancer diagnosis to surgery than those
without comorbidity. The identification of this pattern may
provide insights for further etiological and preventive
research and help to identify patients at a higher risk for
poorer cancer outcomes and suboptimal treatment.
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